{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:09Z","timestamp":1761057249190},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":7605,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1023\/a:1008316323854","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"360-361","source":"Crossref","is-referenced-by-count":3,"title":["Epirubicin in a breast cancer patient with Gilbert's syndrome: Apparent lack of major pharmacokinetic alterations"],"prefix":"10.1016","volume":"10","author":[{"given":"M.","family":"Riggi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Poggesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.B.","family":"Regazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fittipaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.J.","family":"Seematter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008316323854_bb0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2165\/00003088-199426060-00002","article-title":"Clinical pharmacokinetics of epirubicin","volume":"26","author":"Robert","year":"1994","journal-title":"Clin Pharmaco-kinet"},{"key":"10.1023\/A:1008316323854_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/phrs.1993.1002","article-title":"The need for pharmacokinetics protocols in special cases","volume":"27","author":"Regazzi","year":"1993","journal-title":"Pharmacol Res"},{"key":"10.1023\/A:1008316323854_bb0015","series-title":"Cancer Chemother Pharmacol","first-page":"99","article-title":"Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines","author":"Robert","year":"1993"},{"key":"10.1023\/A:1008316323854_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","article-title":"Genetic variations in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert\u2019s syndrome","volume":"347","author":"Monaghan","year":"1996","journal-title":"Lancet"},{"key":"10.1023\/A:1008316323854_bb0025","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1200\/JCO.1994.12.6.1259","article-title":"Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen","volume":"12","author":"Jones","year":"1994","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1023\/A:1008316323854_bb0030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00007691-199310000-00016","article-title":"A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma","volume":"15","author":"Andersen","year":"1993","journal-title":"Therapeutic Drug Monit"},{"key":"10.1023\/A:1008316323854_bb0035","first-page":"221","article-title":"Epirubicin and doxorubicin comparative metabolism and pharmacokinetics","volume":"21","author":"Camaggi","year":"1988","journal-title":"A crossover study. Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008316323854_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00684959","article-title":"Multiple dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer","volume":"28","author":"Jakobsen","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008316323854_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bjc.1992.353","article-title":"Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry tests","volume":"66","author":"Twelves","year":"1992","journal-title":"Br J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419571277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419571277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/10\/3\/360\/19477423\/10-3-360b.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T23:29:01Z","timestamp":1582241341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419571277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["S0923753419571277"],"URL":"https:\/\/doi.org\/10.1023\/a:1008316323854","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}